Blood-based biomarkers in hypothalamic-pituitary axes for the risk of dementia or cognitive decline: a systematic review and meta-analysis

Yi-Jun Ge[1,*], Wei Xu[1,*,&], Chen-Chen Tan[1], Lan Tan[1,&]

[1]Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
*Equal contribution

Correspondence to: Wei Xu, Lan Tan; **email:** 1037219730@qq.com, dr.tanlan@163.com

ABSTRACT

Blood-based biomarkers are ideal candidates for dementia prediction. This systematic review and meta-analysis aimed to evaluate longitudinal relationships of blood hormones and hormone-binding proteins in hypothalamic-pituitary (HP) axes with dementia or cognitive decline. PubMed, MEDLINE, EMBASE, PsycINFO, and BIOSIS were systematically searched from 1919 to June 2020. Fifteen types of hormones and four types of hormone-binding proteins were measured in 48 prospective studies. Increased risk of dementia or cognitive decline could be predicted by elevated blood concentrations of free-thyroxine (free-T4, RR = 1.06, p = 0.001) and sex hormone-binding globulin (SHBG, RR = 1.10, p = 0.025). Lower thyroid-stimulating hormone (TSH) levels within (RR = 1.28, p < 0.001) and below (RR = 1.27, p = 0.004) the normal range were both risky. Current evidence suggests the alterations of multiple blood molecules in HP axes, especially TSH, free-T4, and SHBG precede the incidence of dementia or cognitive decline. The underpinning etiology remains to be elucidated in the future.

INTRODUCTION

Dementia, with cognitive impairment as the core symptom, has brought tremendous burden on health and social care in the 21st century [1]. Aging is accompanied by an increased prevalence of dementia, as well as an altered blood concentration of multiple hormones and hormone-binding proteins [2]. However, it remains disputable whether the hormonal change is involved in the occurrence of cognitive disorders, or it is merely part of the normal aging progress. If the hormonal changes in blood could predict cognitive deterioration, the blood tests of hormones might be greatly valuable in screening and identifying individuals at high risk of developing dementia, especially considering that they are less invasive and more accessible than other approaches, such as cerebrospinal fluid and PET imaging [3].

In past decades, lines of evidence suggested that the dysregulation of hypothalamic-pituitary-thyroid (HPT)

[4], -gonadal (HPG) [5], -somatic (HPS) [6], and -adrenal (HPA) [7] axes was linked to cognitive impairments. The homeostasis disturbance might be caused by the aberrant metabolism of hormones *per se* or changed bioavailable fractions due to abnormal levels of hormone-binding proteins [8]. Higher brain amyloid burden [9] and greater brain atrophy [10] were detected in individuals who had alterations in hormone levels, providing insight into pathophysiological mechanisms. Still, the risk for dementia and cognitive decline caused by hormonal changes was under debate, which might be attributed to different study designs, inconsistent outcome criteria, and mixed fractions of hormones. For instance, testosterone and estradiol were found to impart no or detrimental effects on cognition in recent meta-analyses of randomized controlled trials (RCTs) [11, 12]. These findings posed a challenge to the traditional view that they were both neuroprotective [8, 13]. To date, most studies in this topic only select

certain types of hormones instead of exploring the whole hypothalamic-pituitary (HP) axes. It should be noted that these axes share common anatomical basis and similar negative feedback loops, suggesting potential common pathophysiological pathways to cognitive deterioration.

Herein, we aimed to evaluate the relationships of hormones and hormone-binding proteins in HP axes with all-cause dementia and cognitive decline based on prospective studies.

RESULTS

Study selection and characteristics

Figure 1 summarizes the selection process. In brief, the search strategy returned 52,185 records, from which we excluded 51,892 after screening the title or abstract, leaving 293 potentially eligible publications. After reviewing the full-text, 247 articles were further excluded. In addition, two eligible articles were identified through screening of reference lists. Finally, a

Figure 1. Literature search for the systematic review and meta-analysis. Abbreviations: DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E2, estradiol; FSH, follicle-stimulating hormone; GH, growth hormone; HPA, hypothalamic-pituitary-adrenal; HPG, hypothalamic-pituitary-gonadal; HPT, hypothalamic-pituitary-thyroid; HPS, hypothalamic-pituitary-somatic; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein; LH, luteinizing hormone; rT3, reverse triiodothyronine; SHBG, sex hormone-binding globulin; T, testosterone; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.

total of 48 articles were included in the systematic review and meta-analysis, including one with unpublished data.

Table 1 exhibits the study characteristics of all included studies. In total, 15 types of hormones and 4 types of hormone-binding proteins involving HPT, HPG, HPS and HPA axes were systematically reviewed. Hormones identified were thyroid-stimulating hormone (TSH) [10, 14–31], thyroxine (T4) [10, 17–21, 23, 26–28, 30], triiodothyronine (T3) [10, 17, 23, 28], and reverse triiodothyronine (rT3) [10] in HPT axis; luteinizing hormone (LH) [32, 33], follicle-stimulating hormone (FSH) [32], testosterone (T) [8, 32–45], dihydrotestosterone (DHT) [32, 33], estrone (E1) [32, 41, 46], and estradiol (E2) [8, 32–34, 36, 38, 39, 41, 43, 45–48] in HPG axis; insulin-like growth factor (IGF) -I [49–56], and IGF-II [51] in HPS axis; dehydroepiandrosterone sulfate (DHEAS) [42, 57], aldosterone [55] and cortisol [58] in HPA axis. Hormone-binding proteins identified were sex hormone-binding globulin (SHBG) [32, 33, 37–40] in HPG axis; insulin-like growth factor-binding protein (IGFBP)-1 [52, 56] IGFBP-2 [59] and IGFBP-3 [49, 51, 52, 56] in HPS axis.

Out of the 48 eligible articles, 45 were community or population-based, and the other three studies were composed of patients with mild cognitive impairment (MCI) recruited from memory clinics. Total sample size of each axis ranged from 4,626 (HPA axis) to 61,496 (HPT axis). The mean ages of participants in all four axes were above 65 years at baseline, so samples in this review represent predominantly older people. Females were a majority of HPT (62%) axis, a minority of HPG (22%) and HPS (38%) axes and accounted for almost half in HPA (56%) axis. Gender differences in these axes were discussed below. Most studies were performed in western countries, except two in Asia [29, 35]. About half of the studies (22 out of 48) described they used morning fasting blood samples. The mean follow-up period of all included studies ranged from 1 to 21.9 years (median, 5.1 years). The mean quality score of each biomarker ranged from 6 to 9 stars, suggesting the overall quality was good.

Hypothalamic-pituitary-thyroid (HPT) axis

TSH and free-T4 levels were associated with the risk of dementia or cognitive decline (Figure 2). Higher TSH within the normal range represented a lower risk of dementia or cognitive decline (N=7, RR=0.77, 95% CI=0.67-0.90, I^2=32.0%). However, the statistical significance was lost when meta-analyzing TSH level across the normal range. In additional analysis, we further proved that it was low but not high TSH level was associated with an increased risk of dementia or cognitive decline, regardless the normal range (below normal range *vs.* normal rage: N=7, RR=1.27, 95% CI=1.08-1.49, I^2=40.3%; lowest *vs.* middle quantile within the normal rage: N=5, RR=1.28, 95% CI=1.13-1.46, I^2=0.0%). Higher free-T4 (the unbound T4 in circulation) also increased the risk of dementia or cognitive decline (N=10, RR=1.06, 95% CI=1.02-1.10, I^2=16.8%). Four studies provided gender-specific data. Consistent findings were high free-T4 was detrimental to cognition in male [19, 27] while TSH level was not associated with the risk in male [19, 24, 27]. The intermediate concentration of TSH in female tended to have the lowest risk of dementia or cognitive decline [24, 26]. Egger's test did not indicate any evidence of publication bias regarding TSH across the normal range (p=0.39) or free-T4 (p=0.07).

Hypothalamic-pituitary-gonadal (HPG) axis

Figure 3 shows the results in HPG axis stratified by gender. Higher SHBG increased the risk of dementia or cognitive decline in male (N=6, RR=1.06, 95% CI=1.00-1.13, I^2=24.8%), female (N=1, RR=1.30, 95% CI=1.10-1.70) and both genders (N=7, RR=1.10, 95% CI=1.01-1.20, I^2=46.4%). Gender differences were observed regarding the effect of gonadal hormones. In female, higher total-E2 was risky (N=4, RR=1.35, 95% CI=1.00-1.82, I^2=13.8%), while bio-E2 and free-E2 were not. Higher estrone was also risky in female (N=1, RR=1.40, 95% CI=1.01-1.82). In male, none of the androgens was associated with dementia or cognitive decline, though a protective tendency had been detected. Neither estrogens in male nor androgens in female reached statistical significance.

Hypothalamic-pituitary-somatic (HPS) axis

IGFBP-2, the most predominant IGFBP in the brain, is the only blood biomarker in HPS axis associated with dementia risk (Figure 4). Result from the Framingham Heart Study Offspring cohort showed elevated circulating IGFBP-2 levels increased the dementia risk with a relatively large effect size (RR=2.89, 95% CI=1.63-5.13). We conducted a subgroup analysis regarding IGF-I according to gender and did not find gender difference.

Hypothalamic-pituitary-adrenal (HPA) axis

The number of studies and participants regarding blood molecules in HPA axis was limited (Figure 5). Only DHEAS was found to be a candidate biomarker for the risk of dementia or cognitive decline. Higher blood level of DHEAS was protective (N=2, RR=0.69, 95% CI=0.50-0.96, I^2=0.0%).

Table 1. Characteristics of prospective studies included in the systematic review and meta-analysis.

Study	Mean age; female	Biomarker	Sample for analysis; observation	Main outcome
Hypothalamic-pituitary-thyroid (HPT) axis				
Annerbo et al., 2006	65.0; 52%	TSH (across)	93; 6y	AD
Annerbo et al., 2009	81.0; 75%	TSH (across)	200; 6.7y	AD
Aubert et al., 2017	75.1; 52%	low TSH, high TSH	2,251; 9y	dementia
Cappola et al., 2015	74.5; 56%	TSH (within), free-T4, total-T3	1,824; 17y	dementia
Castellano et al., 2013	75.9; 29%	TSH (within), total-T4, free-T4, total-T3, free-T3	62; 3y	cognitive decline
Chaker et al., 2016	64.9; 57%	TSH (across), TSH (within), free-T4	7,966; 8y	dementia
Dejong et al., 2006	72.3; 51%	TSH (across), low TSH, high TSH, free-T4, total-T3, rT3	1,025; 5.5y	dementia, AD
Dejong et al., 2009	78.1; 0%	TSH (across), low TSH, high TSH, total-T4, free-T4	665; 4.7y	dementia, AD
Folkestad et al., 2020	63; 77%	low TSH	13,445; 7.3y	dementia
Forti et al., 2012	73.3; 53%	TSH (across), high TSH, free-T4	660; 3.8y	dementia and its subtypes
George et al., 2019	57; 56%	TSH (across), low TSH, high TSH, free-T4	12,481; 21.9y	dementia
Hogervorst et al., 2008	73.6; 51%	TSH (across), free-T4	899; 2y	cognitive decline
Kalmijn et al., 2000	68.8; 72%	low TSH, high TSH	1,730; 2.1y	dementia, AD
Moon et al., 2014	72.5; 50%	TSH (within)	313; 5y	MCI or dementia
Quinlan et al., 2019	65.0; 54%	TSH (across), free-T4, free-T3	302; 2.8y	dementia and its subtypes
Tan et al., 2008	71; 59%	TSH (across), TSH (within)	1,600; 12.7y	dementia, AD
Vadiveloo et al., 2011	66.5; 77%	low TSH	12,115; 5.6y	dementia
Volpato et al., 2002	77.2; 100%	TSH (within), total-T4	464; 3y	cognitive decline
Yeap et al., 2012	78.3; 0%	TSH (across), TSH (within), high TSH, free-T4	3,401; 5.9y	dementia
Hypothalamic-pituitary-gonadal (HPG) axis				
Carcaillon et al., 2014	74.5; 0%	total-T, bio-T, total-E2	503; 3.1y	dementia and its subtypes
Carcaillon et al., 2014	75.2; 100%	total-T, total-E2, bio-E2	675; 4y	dementia, AD
Chu et al., 2010	72.7; 0%	bio-T	153; 1y	dementia, AD
Ford et al., 2018	77.0; 0%	LH, total-T, free-T, DHT, total-E2, SHBG	4,069; 10.5y	dementia
Geerlings et al., 2003	69.8; 54%	total-E2, bio-E2	1,031; 6.3y	dementia and its subtypes
Geerlings et al., 2006	77.4; 0%	bio-T, bio-E2	2,300; 6.1y	dementia and its subtypes
Hogervorst et al., 2010	74; 0%	total-T, free-T, SHBG	240; 2y	cognitive decline
Hsu et al., 2015*	76.9; 0%	FSH, LH, total-T, free-T, DHT, estrone, total-E2, SHBG	546; 5y	cognitive decline
Laughlin et al., 2010	69.0; 100%	estrone, total-E2, bio-E2	343; 4y	cognitive decline
LeBlanc et al., 2010	73.6; 0%	free-T, free-E2, SHBG	1,001; 4.5y	cognitive decline

|				
Moffat et al., 2004	66.3; 0%	total-T, free-T, SHBG	574; 19.1y	dementia, AD
Muller et al., 2009	77.4; 0%	total-T, free-T, estrone, total-E2, free-E2	218; 4y	cognitive decline
Muller et al., 2010	77.4; 70%	SHBG	731; 5.2y	dementia, AD
Ponholzer et al., 2009**	75.7; 0%	total-T	146; 5y	AD
Ravaglia et al., 2007	73.9; 54%	free-T, total-E2	809; 3.8y	dementia and its subtypes
Suravarapu et al., 2006	72.7; 0%	total-T, bio-T	128; 10.3y	dementia
Yaffe et al., 2000	71.4; 100%	total-T, free-T, bio-E2, free-E2	292; 6y	cognitive decline
Yaffe et al., 2007	75.2; 45%	bio-E2	736; 2y	cognitive decline
Hypothalamic-pituitary-somatic (HPS) axis				
Almeida et al., 2017	76.9; 0%	total IGF-I, IGFBP-3	3,432; 9.2y	dementia
Dik et al., 2003	75.5; 51%	total IGF-I	1,022; 3y	cognitive decline
Green et al., 2014	56.1; 0%	total IGF-I, bio IGF-I, total IGF-II, IGFBP-3	745; 17y	dementia
Kalmijn et al., 2000	67.4; 50%	total IGF-I, bio IGF-I, free IGF-I, IGFBP-1, IGFBP-3	166; 1.9y	cognitive decline
McGrath et al., 2019	68.7; 53%	IGFBP-2	1,596; 11.8y	dementia, AD
Paulsen et al., 2019***	66.9; 59%	total IGF-I	970; 5y	MCI or dementia
Quinlan et al., 2017	64.6; 57%	total IGF-I	342; 3.6y	dementia and its subtypes
Westwood et al., 2014	65.0; 57%	total IGF-I	3,582; 7.4y	dementia, AD
Zhang et al., 2020	76.1; 55%	total IGF-I, bio IGF-I, IGFBP-1, IGFBP-3	655; 6.9y	MDCI
Hypothalamic-pituitary-adrenal (HPA) axis				
Kalmijn et al., 1998	67.1; 50%	DHEAS	169; 1.9y	cognitive decline
Paulsen et al., 2019***	66.9; 59%	aldosterone	970; 5y	MCI or dementia
Ponholzer et al., 2009**	75.7; 0%	DHEAS	146; 5y	AD
Schrijvers et al., 2011	72.0; 38%	cortisol	3,341; 7.1y	dementia, AD

Abridged table. Please see online Supplementary Table 1 for more detailed information.

*Unpublished data acquired by contacting with authors. **An overlapped article concerning HPG and HPA axes. ***An overlapped article concerning HPA and HPS axes. Abbreviations: AD, Alzheimer's disease; bio, bioavailable; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; E2, estradiol; FSH, follicle-stimulating hormone; high TSH, TSH level above normal range; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein; LH, luteinizing hormone; low TSH, TSH level below normal range; MCI, mild cognitive impairment; MDCI, multiple-domain cognitive impairment; rT3, reverse triiodothyronine; SHBG, sex hormone-binding globulin; T, testosterone; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; TSH (across), TSH level across normal range; TSH (within), TSH level within normal range.

DISCUSSION

In this study, we found the increased risk of dementia or cognitive decline could be predicted by a dropped blood concentration of TSH or DHEAS, as well as an elevated blood concentration of free-T4, SHBG, or IGFBP-2. In subgroup analysis, elevated levels estrogen (total-E2 and estrone) in female were also associated with the

Figure 2. Higher concentrations of blood biomarkers in HPT axis and the risk of dementia or cognitive decline. *Only one of the five studies reported case and sample size. Abbreviations: rT3, reverse triiodothyronine; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.

	Case/sample	I^2(%)	Quality score: mean (SD)
TSH, across normal range	4,004/29,292	63.9	7.6 (1.6)
low vs. normal	3,748/43,399	40.3	7.6 (1.4)
high vs. normal	3,157/22,126	0.0	8.0 (1.6)
TSH, within normal range	1,269/15,492	32.0	8.1 (1.1)
lowest vs. middle	395/5,975*	0.0	8.0 (1.3)
highest vs. middle	330/5,966*	54.5	8.0 (1.3)
total-T4	232/1,191	70.0	9.0 (0.0)
free-T4	3,930/29,285	16.8	7.8 (1.7)
total-T3	323/2,911	26.1	7.0 (1.4)
free-T3	113/364	72.1	7.5 (1.5)
rT3	63/1,025	-	6.0 (-)

Figure 3. Higher concentrations of blood biomarkers in HPG axis and the risk of dementia or cognitive decline. *One of the studies did not report case and sample size. Abbreviations: bio, bioavailable; DHT, dihydrotestosterone; E2, estradiol; FSH, follicle-stimulating hormone; LH, luteinizing hormone; SHBG, sex hormone-binding globulin; T, testosterone.

	Case/sample	I^2(%)	Quality score: mean (SD)
LH	559/4,615	0.0	8.0 (0.0)
FSH	60/546	-	8.0 (-)
total-T	849/6,424	45.1	7.5 (0.8)
	169/967	0.0	7.5 (0.5)
bio-T	314/3,084	77.2	7.5 (0.5)
free-T	726/6,023*	36.3	7.6 (0.7)
	108/725	0.0	8.5 (0.5)
DHT	559/4,615	0.0	8.0 (0.0)
estrone	104/464	0.0	7.5 (0.5)
	103/343	-	6.0 (-)
total-E2	800/6,182	54.7	7.8 (0.7)
	382/2,012	13.8	7.5 (1.1)
bio-E2	271/3,012	62.6	7.7 (0.5)
	386/2,053	81.1	7.2 (0.8)
free-E2	44/218*	59.4	7.0 (0.0)
	37/292	-	8.0 (-)
SHBG	693/5,646*	24.8	7.7 (0.8)
	96/514	-	9.0 (-)

high risk. Among these blood-based biomarkers, evidence of three (TSH, free-T4 and SHBG) was robust on the basis of the large sample size (>5,000), consistency (I^2<50%), and high quality (NOS >7). Figure 6 shows a map of hormones in HP axes, their hormone-binding proteins, and the risk for dementia or cognitive decline.

Low TSH and high free-T4 indicate hyperthyroidism and were both detrimental to cognition in our meta-analysis. It had been demonstrated that such a distribution of hormone levels was linked to multiple adverse outcomes, including atrial fibrillation and heart failure [17], some of which were established risk factors for dementia. Hence, the increased risk of dementia or cognitive decline might be explained by the cardiovascular side effects to a certain extent.

All eligible studies on total-E2 in female excluded hormone therapy users, so they represented the endogenous total-E2. The detrimental effect of endogenous high total-E2 in female was consistent with a meta-analysis of RCTs that reported exogenous estrogen plus progestin therapy increased the risk of probable dementia in female [11]. It has been suggested that estrogens were neuroprotective for younger postmenopausal women while neurotoxic for older women [60]. Females in eligible studies we included for this topic were old (mean age, 69-75 years), so our data supported this hypothesis. The dementia risk of total-E2 in female could also be explained by the free hormone hypothesis, as we observed bioavailable E2 failed to predict the risk, while high SHBG (the predominant E2-binding protein in circulation) was associated with higher risk of dementia. Consistently, we recently reported that higher levels of plasma SHBG contributed to accelerated Alzheimer's pathology, declined brain metabolism, and atrophy of the hippocampus, which were known to be involved in the pathophysiology of cognitive decline [61]. The null finding of endogenous androgens in male was in line with a recent evidence-based guideline, indicating exogenous testosterone therapy in older men had little to no effect on cognition [62].

Taken together, the alteration in blood concentration of multiple hormones and hormone-binding proteins in HP


Figure 4. Higher concentrations of blood biomarkers in HPS axis and the risk of dementia or cognitive decline. Abbreviations: bio, bioavailable; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein.

Figure 5. Higher concentrations of blood biomarkers in HPA axis and the risk of dementia or cognitive decline. Abbreviation: DHEAS, dehydroepiandrosterone sulfate.

axes precedes the incidence of dementia and cognitive decline, though the related etiology is a subject of ongoing research and debate. Interestingly, high SHBG is generally accompanied by low TSH, high free-T4, and high estrogen [63], and they were all associated with a high risk of dementia or cognitive decline in our meta-analysis. This linkage suggests the risk for dementia and cognitive decline is not merely caused by some individual components, but the whole HP axes is involved. The hypothesis was supported by other pathological and neuroimaging studies [64]. Hypothalamic neuronal loss, atrophy and metabolism reduction were detected in patients with neurodegenerative diseases compared to healthy controls. Hypothalamic dysfunctions, including disrupted regulation of body weight, circadian rhythm and sleep were also common in patients with dementia.

Admittedly, effect sizes of most biomarkers in this review were relatively small, but still valuable for dementia prediction, especially in primary care setting or large-scale screening. There is a high prevalence of thyroid disease in the elderly population, and many apparently healthy individuals receive a routine examination of thyroid function [4]. Meanwhile, plasma SHBG has been applied to clinical examinations of various metabolic diseases. Therefore, we recommend greater attention be paid to cognitive besides metabolic effects when the concentration of these biomarkers in blood deviates from normal. These results also provided potential therapeutic targets for dementia. Of note, our findings were based on the population level and thus could not be extended directly to an individual level. Future studies for accurate prediction of cognitive. decline at the individual level should consider age,

Figure 6. Map of hormones in HP axes, their hormone-binding proteins and the risk of dementia and cognitive decline. Font colours indicate the effect on risk of dementia or cognitive decline of higher concentrations of blood biomarkers. Subgroups are shown below biomarker names. The results of FSH, LH, and IGF-II were derived from males only. Abbreviations: ACTH, adrenocorticotropic hormone; bio, bioavailable; CBG, corticosteroid-binding globulin; CRH, corticotropin-releasing hormone; DHEAS, dehydroepiandrosterone sulphate; DHT, dihydrotestosterone; FSH, follicle-stimulating hormone; GH, growth hormone; GHRH, growth hormone-releasing hormone; GnRH, gonadotropin-releasing hormone; IGF, insulin-like growth factor; IGFBP, insulin-like growth factor-binding protein; LH, luteinizing hormone; rT3, reverse triiodothyronine; SHBG, sex hormone-binding globulin; T3, triiodothyronine; T4, thyroxine; TBG, thyroxine-binding globulin; TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone.

gender, comorbidities, and the measurement techniques. In our subgroup analysis, gender differences were observed regarding the effect of several biomarkers on cognition. This could be explained by natural differences in hormone concentrations of both genders. The prevalence of dementia phenotypes among men and women differs [65], which could also be a possible explanation.

Our study has several limitations. First, although a total of 48 studies were included, not all of them covered the same biomarkers. For most biomarkers, the actual number of studies was insufficient to draw a firm conclusion, so the results should be interpreted with caution and warrant replication in more prospective cohorts. Likewise, subtypes of dementia were unable to be distinguished due to the limited number of studies. Second, only studies with RR and 95% CI were included, so some valuable information derived from different statistical methods might be omitted. Third, the U-shaped association between certain hormones and dementia risk had been suggested [8, 24]. However, we could not conduct the dose-response analysis to test the hypothesis because of the heterogeneous units and reference levels among different laboratories. Fourth, multiple factors are associated with the concentration of hormones, and hormones themselves follow complex regulatory pathways. Although maximally adjusted estimates were applied, over- or under-adjustment may exist and cofound the results. Fifth, diurnal change is an important consideration to develop blood-based biomarkers. We had no means to further investigate this issue for half studies in the meta-analysis did not control this aspect sufficiently.

Despite these caveats, this study had a number of strengths. First, it was comprehensive. We explored hormones and hormone-binding proteins in HP axes as wildly as possible to find the potential connection of biomarkers in different axes for their impact on cognition. Second, as only prospective studies were included, we were able to predict the risk of dementia and cognitive decline before the disease onset. Third, the participants included in our study were mainly community-dwelling elders selected from multiple sampling, so our findings could provide recommendations for this specific population.

In conclusion, we found the endocrine profile of low TSH, high free-T4 and high SHBG was associated with an elevated risk of dementia or cognitive decline. The underpinning etiology remains to be elucidated. Future efforts were needed to develop individualized blood-based models for predicting dementia and cognitive decline using multiple elements, including hormones and hormone-binding proteins.

MATERIALS AND METHODS

This systematic review and meta-analysis was prepared following recommendations of the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) groups [66, 67].

Search strategy

We systematically searched PubMed, MEDLINE, EMBASE, PsycINFO and BIOSIS from 1919 to June 29, 2020 without language restriction, using the search terms "hormone", "thyroid stimulating hormone", "TSH", "thyrotropin", "thyroxine", "triiodothyronine", "hypothyroidism", "hyperthyroidism", "thyroid", "follicle stimulating hormone", "FSH", "luteinizing hormone", "LH", "lactogen", "pituitary", "sex hormone", "androgen", "testosterone", "dihydrotestosterone", "DHT", "estrogen", "estradiol", "estriol", "estrone", "progesterone", "sex hormone binding globulin", "SHBG", "growth hormone", "GH", "insulin like growth factor", "IGF", "corticotropin", "adrenocorticotropic hormone", "ACTH", "dehydroepiandrosterone, "DHEA", "dehydroepiandrosterone sulfate", "DHEAS", "cortisol", "adrenal", "dementia", "Alzheimer", "cognitive" and "MCI". The reference lists of eligible articles and relevant reviews were hand-searched for additional citations.

Selection criteria

Eligible studies had to meet the following criteria simultaneously: (1) had a prospective design (prospective cohort, case-cohort or nested case-control); (2) participants were selected from general populations or memory clinic without dementia; (3) dementia or cognitive decline were recorded by use of well-defined criteria; (4) relative risks (RRs) and 95% confidence intervals (CIs) regarding the association between endogenous blood hormones or hormone-binding proteins in HP axes and dementia or cognitive decline were initially given or could be calculated by information derived from articles. Studies were excluded if they failed to meet any criteria described above. Studies on hormone replacement therapy were not included because this topic had been investigated in recent systematic reviews [11, 12]. If a cohort related to the same biomarker had been published more than once, we chose the most recent publication. The eligibility of each study was assessed by two investigators independently. Disagreements regarding eligibility were resolved by consensus.

Data extraction

The following information was extracted: first author, publication year, study design, cohort name, source,

country, duration of follow-up, follow-up rate, demographic characteristics (age, gender, case and sample size, whether dementia and hormonal medication users were excluded at baseline), exposure (type of biomarkers, whether fasting morning blood sample was collected, hormone measurement technique, coefficients of variation), and outcome (dementia or cognitive decline and related diagnostic criteria, confounders adjusted). The maximally adjusted estimate was applied when several adjusted models were reported in one study. We contacted corresponding authors for further explanation regarding uncertain and missing data. Two investigators independently extracted data. Disagreements were settled by consensus with the help of a third investigator.

Quality assessment

The Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. The scale evaluates three domains: selection, comparability, and outcome ascertainment. In this systematic review, we graded the quality as high (7-9 stars), moderate (4-6 stars), and poor (1-3 stars).

Statistical analysis

Risk estimates were expressed as RRs with 95% CIs. A RR above one indicates the high level in blood increases the risk of dementia or cognitive decline, while a RR below one refers to the low level increases the risk. Hazard ratios (HRs) were deemed to be equivalent to RRs. As odds ratios (ORs) often overestimate the true effect, we converted them to RRs using the following formula [68]:

$$RR_{adjusted} = OR_{adjusted} / [(1 - P_0) + (P_0 \times OR_{adjusted})]$$

P_0 indicates the incidence of outcome in the reference group or the total sample (when the former is not available). If feasible, RRs and 95% CIs were estimated manually by raw data derived from the text when the original data was not available. We combined the continuous data (*i.e.*, RR per unit increment) with categorical data (*i.e.*, RR of highest *vs.* lowest quantile), and we chose the latter in priority when they were both provided in the same study. For categorical data, if original risk estimates were not presented as the top versus bottom quantile, we graded the bottom quantile as the reference level and recalculated the risk estimate based on a proposed method [69]. The units of hormone levels were not normalized due to the heterogeneous measurement approaches among studies.

The free or bioavailable hormones cross the blood-brain-barrier more readily and may be better correlated with cognition [48]. Since some hormones have been reported as different fractions according to bioavailability, we pooled them separately. For those bioavailable fractions, direct laboratory measurements and prediction formulas estimating their blood concentrations were combined. As the normal range of TSH was available in most studies, we defined its four categories based on the normal range: across the normal range, within the normal range, above the normal range (high TSH) and below the normal range (low TSH). Additional analysis was conducted to further investigate the primary results of TSH, using four comparisons: below normal range *vs.* normal range, above normal range *vs.* normal range, the lowest *vs.* the middle quantile within the normal range, the highest *vs.* the middle quantile within the normal range. Prespecified subgroup analysis according to gender in HPG axis was conducted in case of the possible sex difference.

Heterogeneities between studies were assessed by the I^2 statistic. I^2 values of 25%, 50%, and 75% represent possibly low, moderate, and high heterogeneity, respectively. Publication bias was evaluated by the Egger's test if there were at least 10 eligible studies. RRs and 95% CIs were log-transformed and pooled using random-effects models. If a study reported data only on Alzheimer's disease (AD) and vascular dementia (VD) but no data on all-cause dementia, we used the fixed effects model to calculate its RR and 95% CI to estimate the risk of all-cause dementia before the main synthesis. Dementia was preferred if data on dementia and cognitive decline were both available for the same biomarker measured in the same population. Analyses were conducted using Stata version 12.0 and R version 3.5.2.

Abbreviations

AD: Alzheimer's disease; bio: bioavailable; CI: confidence interval; DHEAS: dehydroepiandrosterone sulfate; E2: estradiol; HP: hypothalamic-pituitary; HPA: hypothalamic-pituitary-adrenal; HPG: hypothalamic-pituitary-gonadal; HPT: hypothalamic-pituitary-thyroid; HPS: hypothalamic-pituitary-somatic; IGF: insulin-like growth factor; IGFBP: insulin-like growth factor-binding protein; RCT: randomized controlled trial; RR: relative risk; SHBG: sex hormone-binding globulin; T4: thyroxine; TSH: thyroid-stimulating hormone.

AUTHOR CONTRIBUTIONS

ACKNOWLEDGMENTS

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare.

Editorial note

&This corresponding author has a verified history of publications using the personal email address for correspondence.

REFERENCES

1. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, et al. Dementia prevention, intervention, and care. Lancet. 2017; 390:2673–734.
https://doi.org/10.1016/S0140-6736(17)31363-6
PMID:28735855

2. Kaufman JM, Lapauw B, Mahmoud A, T'Sjoen G, Huhtaniemi IT. Aging and the male reproductive system. Endocr Rev. 2019; 40:906–72.
https://doi.org/10.1210/er.2018-00178
PMID:30888401

3. Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018; 14:639–52.
https://doi.org/10.1038/s41582-018-0079-7
PMID:30297701

4. Chaker L, Cappola AR, Mooijaart SP, Peeters RP. Clinical aspects of thyroid function during ageing. Lancet Diabetes Endocrinol. 2018; 6:733–42.
https://doi.org/10.1016/S2213-8587(18)30028-7
PMID:30017801

5. Blair JA, McGee H, Bhatta S, Palm R, Casadesus G. Hypothalamic-pituitary-gonadal axis involvement in learning and memory and Alzheimer's disease: more than "just" estrogen. Front Endocrinol (Lausanne). 2015; 6:45.
https://doi.org/10.3389/fendo.2015.00045
PMID:25859241

6. Milman S, Huffman DM, Barzilai N. The somatotropic axis in human aging: framework for the current state of knowledge and future research. Cell Metab. 2016; 23:980–89.
https://doi.org/10.1016/j.cmet.2016.05.014
PMID:27304500

7. Gardner M, Lightman S, Kuh D, Comijs H, Deeg D, Gallacher J, Geoffroy MC, Kivimaki M, Kumari M, Power C, Hardy R, Richards M, Ben-Shlomo Y. Dysregulation of the hypothalamic pituitary adrenal (HPA) axis and cognitive capability at older ages: individual participant meta-analysis of five cohorts. Sci Rep. 2019; 9:4555.
https://doi.org/10.1038/s41598-019-40566-x
PMID:30872618

8. Carcaillon L, Brailly-Tabard S, Ancelin ML, Tzourio C, Foubert-Samier A, Dartigues JF, Guiochon-Mantel A, Scarabin PY. Low testosterone and the risk of dementia in elderly men: impact of age and education. Alzheimers Dement. 2014; 10:S306–14.
https://doi.org/10.1016/j.jalz.2013.06.006
PMID:24035146

9. Toledo JB, Toledo E, Weiner MW, Jack CR Jr, Jagust W, Lee VM, Shaw LM, Trojanowski JQ, and Alzheimer's Disease Neuroimaging Initiative. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2012; 8:483–89.
https://doi.org/10.1016/j.jalz.2011.08.008
PMID:23102118

10. de Jong FJ, den Heijer T, Visser TJ, de Rijke YB, Drexhage HA, Hofman A, Breteler MM. Thyroid hormones, dementia, and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2006; 91:2569–73.
https://doi.org/10.1210/jc.2006-0449 PMID:16636121

11. Gartlehner G, Patel SV, Feltner C, Weber RP, Long R, Mullican K, Boland E, Lux L, Viswanathan M. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force. JAMA. 2017; 318:2234–49.
https://doi.org/10.1001/jama.2017.16952
PMID:29234813

12. Diem SJ, Greer NL, MacDonald R, McKenzie LG, Dahm P, Ercan-Fang N, Estrada A, Hemmy LS, Rosebush CE, Fink HA, Wilt TJ. Efficacy and safety of testosterone treatment in men: an evidence report for a clinical practice guideline by the American college of physicians. Ann Intern Med. 2020; 172:105–18.
https://doi.org/10.7326/M19-0830 PMID:31905375

13. Azcoitia I, Arevalo MA, De Nicola AF, Garcia-Segura LM. Neuroprotective actions of estradiol revisited. Trends Endocrinol Metab. 2011; 22:467–73.
https://doi.org/10.1016/j.tem.2011.08.002
PMID:21889354

14. Annerbo S, Kivipelto M, Lokk J. A prospective study on the development of Alzheimer's disease with regard to thyroid-stimulating hormone and homocysteine. Dement Geriatr Cogn Disord. 2009; 28:275–80.
https://doi.org/10.1159/000242439
PMID:19797897

15. Annerbo S, Wahlund LO, Lökk J. The significance of thyroid-stimulating hormone and homocysteine in the development of Alzheimer's disease in mild cognitive impairment: a 6-year follow-up study. Am J Alzheimers Dis Other Demen. 2006; 21:182–88.
https://doi.org/10.1177/1533317506289282
PMID:16869339

16. Aubert CE, Bauer DC, da Costa BR, Feller M, Rieben C, Simonsick EM, Yaffe K, Rodondi N, and Health ABC Study. The association between subclinical thyroid dysfunction and dementia: the health, aging and body composition (health ABC) study. Clin Endocrinol (Oxf). 2017; 87:617–26.
https://doi.org/10.1111/cen.13458 PMID:28850708

17. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2015; 100:1088–96.
https://doi.org/10.1210/jc.2014-3586 PMID:25514105

18. Chaker L, Wolters FJ, Bos D, Korevaar TI, Hofman A, van der Lugt A, Koudstaal PJ, Franco OH, Dehghan A, Vernooij MW, Peeters RP, Ikram MA. Thyroid function and the risk of dementia: the rotterdam study. Neurology. 2016; 87:1688–95.
https://doi.org/10.1212/WNL.0000000000003227
PMID:27638924

19. de Jong FJ, Masaki K, Chen H, Remaley AT, Breteler MM, Petrovitch H, White LR, Launer LJ. Thyroid function, the risk of dementia and neuropathologic changes: the honolulu-asia aging study. Neurobiol Aging. 2009; 30:600–06.
https://doi.org/10.1016/j.neurobiolaging.2007.07.019
PMID:17870208

20. Forti P, Olivelli V, Rietti E, Maltoni B, Pirazzoli G, Gatti R, Gioia MG, Ravaglia G. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort. Gerontology. 2012; 58:41–49.
https://doi.org/10.1159/000324522 PMID:21430364

21. Hogervorst E, Huppert F, Matthews FE, Brayne C. Thyroid function and cognitive decline in the MRC cognitive function and ageing study. Psychoneuroendocrinology. 2008; 33:1013–22.
https://doi.org/10.1016/j.psyneuen.2008.05.008
PMID:18640783

22. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The rotterdam study. Clin Endocrinol (Oxf). 2000; 53:733–37.
https://doi.org/10.1046/j.1365-2265.2000.01146.x
PMID:11155096

23. Quinlan P, Horvath A, Wallin A, Svensson J. Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer's disease. Psychoneuroendocrinology. 2019; 99:112–19.
https://doi.org/10.1016/j.psyneuen.2018.09.002
PMID:30223192

24. Tan ZS, Beiser A, Vasan RS, Au R, Auerbach S, Kiel DP, Wolf PA, Seshadri S. Thyroid function and the risk of Alzheimer disease: the framingham study. Arch Intern Med. 2008; 168:1514–20.
https://doi.org/10.1001/archinte.168.14.1514
PMID:18663163

25. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011; 96:1344–51.
https://doi.org/10.1210/jc.2010-2693 PMID:21346066

26. Volpato S, Guralnik JM, Fried LP, Remaley AT, Cappola AR, Launer LJ. Serum thyroxine level and cognitive decline in euthyroid older women. Neurology. 2002; 58:1055–61.
https://doi.org/10.1212/wnl.58.7.1055
PMID:11940692

27. Yeap BB, Alfonso H, Chubb SA, Puri G, Hankey GJ, Flicker L, Almeida OP. Higher free thyroxine levels predict increased incidence of dementia in older men: the health in men study. J Clin Endocrinol Metab. 2012; 97:E2230–37.
https://doi.org/10.1210/jc.2012-2108 PMID:22977271

28. Castellano CA, Laurin D, Langlois MF, Fortier M, Tessier D, Gaudreau P, Ferland G, Payette H, Lorrain D, Cunnane SC. Thyroid function and cognition in the euthyroid elderly: a case-control study embedded in quebec longitudinal study – NuAge. Psychoneuroendocrinology. 2013; 38:1772–76.
https://doi.org/10.1016/j.psyneuen.2013.02.013
PMID:23507188

29. Moon JH, Park YJ, Kim TH, Han JW, Choi SH, Lim S, Park DJ, Kim KW, Jang HC. Lower-but-normal serum TSH level is associated with the development or progression of cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging (KLoSHA). J Clin Endocrinol Metab. 2014; 99:424–32.
https://doi.org/10.1210/jc.2013-3385 PMID:24285689

30. George KM, Lutsey PL, Selvin E, Palta P, Windham BG, Folsom AR. Association between thyroid dysfunction and incident dementia in the atherosclerosis risk in

communities neurocognitive study. J Endocrinol Metab. 2019; 9:82–89.
https://doi.org/10.14740/jem588 PMID:32411312

31. Folkestad L, Brandt F, Lillevang-Johansen M, Brix TH, Hegedüs L. Graves' disease and toxic nodular goiter, aggravated by duration of hyperthyroidism, are associated with Alzheimer's and vascular dementia: a registry-based long-term follow-up of two large cohorts. Thyroid. 2020; 30:672–80.
https://doi.org/10.1089/thy.2019.0672
PMID:31984866

32. Hsu B, Cumming RG, Waite LM, Blyth FM, Naganathan V, Le Couteur DG, Seibel MJ, Handelsman DJ. Longitudinal Relationships between Reproductive Hormones and Cognitive Decline in Older Men: The Concord Health and Ageing in Men Project. J Clin Endocrinol Metab. 2015; 100:2223–30.
https://doi.org/10.1210/jc.2015-1016
PMID:25867811

33. Ford AH, Yeap BB, Flicker L, Hankey GJ, Chubb SA, Golledge J, Almeida OP. Sex hormones and incident dementia in older men: the health in men study. Psychoneuroendocrinology. 2018; 98:139–47.
https://doi.org/10.1016/j.psyneuen.2018.08.013
PMID:30144781

34. Carcaillon L, Brailly-Tabard S, Ancelin ML, Rouaud O, Dartigues JF, Guiochon-Mantel A, Scarabin PY. High plasma estradiol interacts with diabetes on risk of dementia in older postmenopausal women. Neurology. 2014; 82:504–11.
https://doi.org/10.1212/WNL.0000000000000107
PMID:24477111

35. Chu LW, Tam S, Wong RL, Yik PY, Song Y, Cheung BM, Morley JE, Lam KS. Bioavailable testosterone predicts a lower risk of Alzheimer's disease in older men. J Alzheimers Dis. 2010; 21:1335–45.
https://doi.org/10.3233/jad-2010-100027
PMID:21504130

36. Geerlings MI, Strozyk D, Masaki K, Remaley AT, Petrovitch H, Ross GW, White LR, Launer LJ. Endogenous sex hormones, cognitive decline, and future dementia in old men. Ann Neurol. 2006; 60:346–55.
https://doi.org/10.1002/ana.20918
PMID:16865684

37. Hogervorst E, Matthews FE, Brayne C. Are optimal levels of testosterone associated with better cognitive function in healthy older women and men? Biochim Biophys Acta. 2010; 1800:1145–52.
https://doi.org/10.1016/j.bbagen.2009.12.009
PMID:20060437

38. LeBlanc ES, Wang PY, Janowsky JS, Neiss MB, Fink HA, Yaffe K, Marshall LM, Lapidus JA, Stefanick ML, Orwoll ES, and Osteoporotic Fractures in Men (MrOS) Research Group. Association between sex steroids and cognition in elderly men. Clin Endocrinol (Oxf). 2010; 72:393–403.
https://doi.org/10.1111/j.1365-2265.2009.03692.x
PMID:19744108

39. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, Resnick SM. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004; 62:188–93.
https://doi.org/10.1212/wnl.62.2.188
PMID:14745052

40. Muller M, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Sex hormone binding globulin and incident Alzheimer's disease in elderly men and women. Neurobiol Aging. 2010; 31:1758–65.
https://doi.org/10.1016/j.neurobiolaging.2008.10.001
PMID:19022535

41. Muller M, van den Beld AW, Grobbee DE, de Jong FH, Lamberts SW. Sex hormones and cognitive decline in elderly men. Psychoneuroendocrinology. 2009; 34:27–31.
https://doi.org/10.1016/j.psyneuen.2008.08.008
PMID:18845400

42. Ponholzer A, Madersbacher S, Rauchenwald M, Jungwirth S, Fischer P, Tragl KH. Serum androgen levels and their association to depression and Alzheimer dementia in a cohort of 75-year-old men over 5 years: results of the VITA study. Int J Impot Res. 2009; 21:187–91.
https://doi.org/10.1038/ijir.2009.10
PMID:19404273

43. Ravaglia G, Forti P, Maioli F, Bastagli L, Montesi F, Pisacane N, Chiappelli M, Licastro F, Patterson C. Endogenous sex hormones as risk factors for dementia in elderly men and women. J Gerontol A Biol Sci Med Sci. 2007; 62:1035–41.
https://doi.org/10.1093/gerona/62.9.1035
PMID:17895444

44. Suravarapu S, Bergstralh EJ, Farmer SA, Knopman DS, Jacobsen SJ, Roberts RO. Dementia and low testosterone and bioavailable testosterone levels in men: possible increased risk. Alzheimer Dis Assoc Disord. 2006; 20:138–40.
https://doi.org/10.1097/00002093-200607000-00003
PMID:16917182

45. Yaffe K, Lui LY, Grady D, Cauley J, Kramer J, Cummings SR. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000; 356:708–12.
https://doi.org/10.1016/S0140-6736(00)02628-3
PMID:11085689

46. Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the rancho bernardo study. Clin Endocrinol (Oxf). 2010; 72:99–106.
https://doi.org/10.1111/j.1365-2265.2009.03599.x
PMID:19508596

47. Geerlings MI, Launer LJ, de Jong FH, Ruitenberg A, Stijnen T, van Swieten JC, Hofman A, Witteman JC, Pols HA, Breteler MM, and Rotterdam Study. Endogenous estradiol and risk of dementia in women and men: the rotterdam study. Ann Neurol. 2003; 53:607–15.
https://doi.org/10.1002/ana.10521 PMID:12730994

48. Yaffe K, Barnes D, Lindquist K, Cauley J, Simonsick EM, Penninx B, Satterfield S, Harris T, Cummings SR, and Health ABC Investigators. Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiol Aging. 2007; 28:171–78.
https://doi.org/10.1016/j.neurobiolaging.2006.10.004
PMID:17097195

49. Almeida OP, Hankey GJ, Yeap BB, Paul Chubb SA, Gollege J, Flicker L. Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3. Mol Psychiatry. 2018; 23:1825–29.
https://doi.org/10.1038/mp.2017.152
PMID:29155799

50. Dik MG, Pluijm SM, Jonker C, Deeg DJ, Lomecky MZ, Lips P. Insulin-like growth factor I (IGF-I) and cognitive decline in older persons. Neurobiol Aging. 2003; 24:573–81.
https://doi.org/10.1016/s0197-4580(02)00136-7
PMID:12714114

51. Green CJ, Holly JM, Bayer A, Fish M, Ebrahim S, Gallacher J, Ben-Shlomo Y. The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging and dementia risk: the caerphilly prospective study. J Alzheimers Dis. 2014; 41:867–75.
https://doi.org/10.3233/JAD-132183
PMID:24705546

52. Kalmijn S, Janssen JA, Pols HA, Lamberts SW, Breteler MM. A prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderly. J Clin Endocrinol Metab. 2000; 85:4551–55.
https://doi.org/10.1210/jcem.85.12.7033
PMID:11134107

53. Quinlan P, Horvath A, Nordlund A, Wallin A, Svensson J. Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. Psychoneuroendocrinology. 2017; 86:169–75.
https://doi.org/10.1016/j.psyneuen.2017.09.018
PMID:28963885

54. Westwood AJ, Beiser A, Decarli C, Harris TB, Chen TC, He XM, Roubenoff R, Pikula A, Au R, Braverman LE, Wolf PA, Vasan RS, Seshadri S. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014; 82:1613–19.
https://doi.org/10.1212/WNL.0000000000000382
PMID:24706014

55. Paulsen AJ, Schubert CR, Pinto A, Carlsson CM, Chappell RJ, Fischer ME, Klein BE, Klein R, Tsai MY, Cruickshanks KJ. Neuroprotective biomarkers and cognitive function in a long-term prospective population-based study of aging US adults. Alzheimer Dis Assoc Disord. 2020; 34:31–39.
https://doi.org/10.1097/WAD.0000000000000341
PMID:31385821

56. Zhang WB, Aleksic S, Gao T, Weiss EF, Demetriou E, Verghese J, Holtzer R, Barzilai N, Milman S. Insulin-like growth factor-1 and IGF binding proteins predict all-cause mortality and morbidity in older adults. Cells. 2020; 9:E1368.
https://doi.org/10.3390/cells9061368
PMID:32492897

57. Kalmijn S, Launer LJ, Stolk RP, de Jong FH, Pols HA, Hofman A, Breteler MM, Lamberts SW. A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly. J Clin Endocrinol Metab. 1998; 83:3487–92.
https://doi.org/10.1210/jcem.83.10.5164
PMID:9768651

58. Schrijvers EM, Direk N, Koudstaal PJ, Kirschbaum C, Hofman A, Tiemeier H, Breteler MM. Associations of serum cortisol with cognitive function and dementia: the rotterdam study. J Alzheimers Dis. 2011; 25:671–77.
https://doi.org/10.3233/JAD-2011-110224
PMID:21483093

59. McGrath ER, Himali JJ, Levy D, Conner SC, DeCarli CS, Pase MP, Courchesne P, Satizabal CL, Vasan RS, Beiser AS, Seshadri S. Circulating IGFBP-2: a novel biomarker for incident dementia. Ann Clin Transl Neurol. 2019; 6:1659–70.
https://doi.org/10.1002/acn3.50854 PMID:31373442

60. Thaung Zaw JJ, Howe PR, Wong RH. Postmenopausal health interventions: time to move on from the women's health initiative? Ageing Res Rev. 2018; 48:79–86.
https://doi.org/10.1016/j.arr.2018.10.005
PMID:30355506

61. Xu W, Su BJ, Shen XN, Bi YL, Tan CC, Li JQ, Cao XP, Dong Q, Tan L, Yu JT, and Alzheimer's Disease Neuroimaging Initiative. Plasma sex hormone-binding globulin predicts neurodegeneration and clinical progression in prodromal Alzheimer's disease. Aging (Albany NY).

2020; 12:14528–41.
https://doi.org/10.18632/aging.103497
PMID:32699184

62. Qaseem A, Horwitch CA, Vijan S, Etxeandia-Ikobaltzeta I, Kansagara D, and Clinical Guidelines Committee of the American College of Physicians. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American college of physicians. Ann Intern Med. 2020; 172:126–33.
https://doi.org/10.7326/M19-0882 PMID:31905405

63. Goldman AL, Bhasin S, Wu FC, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev. 2017; 38:302–24.
https://doi.org/10.1210/er.2017-00025
PMID:28673039

64. Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target of pathology. Cell Metab. 2015; 22:761–76.
https://doi.org/10.1016/j.cmet.2015.08.016
PMID:26365177

65. Snyder HM, Asthana S, Bain L, Brinton R, Craft S, Dubal DB, Espeland MA, Gatz M, Mielke MM, Raber J, Rapp PR, Yaffe K, Carrillo MC. Sex biology contributions to vulnerability to Alzheimer's disease: a think tank convened by the women's Alzheimer's research initiative. Alzheimers Dement. 2016; 12:1186–96.
https://doi.org/10.1016/j.jalz.2016.08.004
PMID:27692800

66. Moher D, Liberati A, Tetzlaff J, Altman DG, and PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8:336–41.
https://doi.org/10.1016/j.ijsu.2010.02.007
PMID:20171303

67. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000; 283:2008–12.
https://doi.org/10.1001/jama.283.15.2008
PMID:10789670

68. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014; 348:f7450.
https://doi.org/10.1136/bmj.f7450 PMID:24464277

69. Orsini N. From floated to conventional confidence intervals for the relative risks based on published dose-response data. Comput Methods Programs Biomed. 2010; 98:90–93.
https://doi.org/10.1016/j.cmpb.2009.11.005
PMID:19959250

Supplementary Table

Please browse Full Text version to see the data of Supplementary Table 1.

Supplementary Table 1. Characteristics of prospective studies included in the systematic review and meta-analysis.